-
There are about 5,000 captive insurance companies in the world, with most being sponsored by U.S. entities, according to information provided by Capstone Associated Services in Houston, TX, which assists organizations with setting up captives.
-
Alcohol abuse is a "significant problem" for surgeons in the United States, with more than 15% of respondents in a nationwide survey signaling that they might have dependency issues, the American College of Surgeons reports.
-
In 2003, a 14-year-old girl went to the emergency department (ED) with complaints of weakness in her legs. The radiology department performed an MRI, but it failed to diagnose an abnormal mass on her spine. When the mass bled four years later, the patient suffered permanent spinal damage.
-
With the link between healthcare worker fatigue and adverse events s well documented, The Joint Commission (TJC) issued a new Sentinel Event Alert: Healthcare worker fatigue and patient safety.
-
A 68-year-old paraplegic male was undergoing occupational therapy to increase his level of independence following a spinal cord injury.
-
One of the biggest challenges IRBs face is keeping up with ethical issue updates during an ever-evolving period technologically, experts say.
-
Three large Ohio academic Clinical and Translational Science Award (CTSA) institutions recently formed an IRB collaboration to allow a central IRB review during multisite studies. This was the first time CTSAs collaborated in this way, and it could serve as a best practice for other research institutions and CTSAs, experts say.
-
Informed consent forms have one very daunting characteristic: They are visually numbing.
-
To ensure that a proposed study or clinical trial can fulfill its goals and remain within ethical guidelines, some IRBs have mandated that protocols go through scientific review prior to submission. The purpose of the review is to ensure that studies are built on a solid scientific foundation to achieve the objectives.
-
Researchers and physicians are increasingly speaking out on the issue of the geriatric population being excluded from clinical trials.
